Colorectal cancer

Nature Reviews Disease Primers

Volumn 1, Issue , 2015, Pages

  Kuipers, Ernst J ^a   Grady, William M ^b,c   Lieberman, David ^d   Seufferlein, Thomas ^e   Sung, Joseph J ^f   Boelens, Petra G ^g   Van De Velde, Cornelis J H ^g   Watanabe, Toshiaki ^h  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b Fred Hutchinson Cancer Research Center   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^d OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^e UNIVERSITY OF ULM   (Germany)

^f CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^g LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^h UNIVERSITY OF TOKYO HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

COLON POLYP; COLON RESECTION; COLORECTAL TUMOR; COMPLICATION; HUMAN; INCIDENCE; LAPAROSCOPY; PROCEDURES; RADIOTHERAPY; RISK FACTOR; TRENDS;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLECTOMY; COLONIC POLYPS; COLORECTAL NEOPLASMS; HUMANS; INCIDENCE; LAPAROSCOPY; RADIOTHERAPY; RISK FACTORS;

EID: 85016401916     PISSN: None     EISSN: 2056676X     Source Type: Journal    
DOI: 10.1038/nrdp.2015.65     Document Type: Article

References (229)

1. Kuipers, E. J., Rösch, T. & Bretthauer, M. Colorectal cancer screening - optimizing current strategies and new directions. Nat. Rev. Clin. Oncol. 10, 130-142 (2013).
2. Warthin, A. S. Heredity with reference to carcinoma: as shown by the study of the cases examined in the pathological laboratory of the University of Michigan. Arch. Intern. Med. 12, 546-555 (1913).
3. Capelle, L. G. et al. Risk and epidemiological time trends of gastric cancer in Lynch syndrome carriers in the Netherlands. Gastroenterology 138, 487-492 (2010).
4. Vasen, H. F. A., Tomlinson, I. & Castells, A. Clinical management of hereditary colorectal cancer syndromes. Nat. Rev. Gastroenterol. Hepatol. 12, 88-97 (2015).
5. Papamichael, D. et al. Treatment of colorectal cancer in older patients: International Society of Geriatric Oncology (SIOG) consensus recommendations 2013. Ann. Oncol. 26, 463-476 (2014).
6. Hurwitz, H. et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 350, 2335-2342 (2004).
7. Heemskerk-Gerritsen, B. A. M. et al. Improved overall survival after contralateral risk-reducing mastectomy in BRCA1/2 mutation carriers with a history of unilateral breast cancer: a prospective analysis. Int. J. Cancer 136, 668-677 (2015).
8. De Jonge, V. et al. Quality evaluation of colonoscopy reporting and colonoscopy performance in daily clinical practice. Gastrointest. Endosc. 75, 98-106 (2012).
9. Valori, R. et al. European guidelines for quality assurance in colorectal cancer screening and diagnosis. First Edition - quality assurance in endoscopy in colorectal cancer screening and diagnosis. Endoscopy 44, SE88-SE105 (2012).
10. GLOBOCAN. GLOBOCAN 2012: estimated cancer incidence, mortality and prevalence worldwide in 2012. GLOBOCAN [online], http://globocan.iarc.fr/ Default.aspx (2015).
11. Rohani-Rasaf, M., Abdollahi, M., Jazayeri, S., Kalantari, N. & Asadi-Lari, M. Correlation of cancer incidence with diet, smoking and socio-economic position across 22 districts of Tehran in 2008. Asian Pac. J. Cancer Prev. 14, 1669-1676 (2013).
12. Draft, C. et al. Global, regional and national levels of age-specific mortality and 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 385, 1990-2013 (2015).
13. Tiwari, A. K., Roy, H. K. & Lynch, H. T. Lynch syndrome in the 21st century: clinical perspectives. QJM http://dx.doi.org/10.1093/qjmed/hcv137 (2015).
14. Pérez-Carbonell, L. et al. Comparison between universal molecular screening for Lynch syndrome and revised Bethesda guidelines in a large population-based cohort of patients with colorectal cancer. Gut 61, 865-872 (2012).
15. Van Lier, M. G. F. et al. Yield of routine molecular analyses in colorectal cancer patients -70 years to detect underlying Lynch syndrome. J. Pathol. 226, 764-774 (2012).
16. Jess, T., Rungoe, C. & Peyrin-Biroulet, L. Risk of colorectal cancer in patients with ulcerative colitis: a meta-analysis of population-based cohort studies. Clin. Gastroenterol. Hepatol. 10, 639-645 (2012).
17. Jess, T. et al. Decreasing risk of colorectal cancer in patients with inflammatory bowel disease over 30 years. Gastroenterology 143, 375-381.e1 (2012).
18. Casta - Milla, C., Chaparro, M. & Gisbert, J. P. Systematic review with meta-analysis: the declining risk of colorectal cancer in ulcerative colitis. Aliment. Pharmacol. Ther. 39, 645-659 (2014).
19. Herrinton, L. J. et al. Incidence and mortality of colorectal adenocarcinoma in persons with inflammatory bowel disease from 1998 to 2010. Gastroenterology 143, 382-389 (2012).
20. World Cancer Research Fund/American Institute for Cancer Research. Continuous update project report. Food, nutrition, physical activity, and the prevention of colorectal cancer. Diet and Cancer Report [online], http://www.dietandcancerreport.org/ cancer-resource-center/downloads/cu/Colorectal-Cancer-2011-Report.pdf (2011).
21. Guraya, S. Y. Association of type 2 diabetes mellitus and the risk of colorectal cancer: a meta-analysis and systematic review. World J. Gastroenterol. 21, 6026-6031 (2015).
22. Fedirko, V. et al. Alcohol drinking and colorectal cancer risk: an overall and dose-response meta-analysis of published studies. Ann. Oncol. 22, 1958-1972 (2011).
23. Liang, P. S., Chen, T.-Y. & Giovannucci, E. Cigarette smoking and colorectal cancer incidence and mortality: systematic review and meta-analysis. Int. J. Cancer 124, 2406-2415 (2009).
24. Botteri, E. et al. Smoking and colorectal cancer: a meta-analysis. JAMA 300, 2765-2778 (2008).
25. Song, M., Garrett, W. S. & Chan, A. T. Nutrients, foods, and colorectal cancer prevention. Gastroenterology 148, 1244-1260.e16 (2015).
26. Dahm, C. C. et al. Dietary fiber and colorectal cancer risk: a nested case-control study using food diaries. 102, 614-626 (2010).
27. Arem, H. et al. Physical activity and cancer-specific mortality in the NIH-AARP Diet and Health Study cohort. Int. J. Cancer 135, 423-431 (2014).
28. Algra, A. M. & Rothwell, P. M. Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials. Lancet Oncol. 13, 518-527 (2012).
29. Doubeni, C. A. et al. Contribution of behavioral risk factors and obesity to socioeconomic differences in colorectal cancer incidence. J. Natl Cancer Inst. 104, 1353-1362 (2012).
30. Erdrich, J., Zhang, X., Giovannucci, E. & Willett, W. Proportion of colon cancer attributable to lifestyle in a cohort of US women. Cancer Causes Control 26, 1271-1279 (2015).
31. Platz, E. A. et al. Proportion of colon cancer risk that might be preventable in a cohort of middle-aged US men. Cancer Causes Control 11, 579-588 (2000).
32. Aleksandrova, K. et al. Combined impact of healthy lifestyle factors on colorectal cancer: a large European cohort study. BMC Med. 12, 168 (2014).
33. Andersen, V. & Vogel, U. Systematic review: interactions between aspirin, and other nonsteroidal anti-inflammatory drugs, and polymorphisms in relation to colorectal cancer. Aliment. Pharmacol. Ther. 40, 147-159 (2014).
34. Nan, H. et al. Association of aspirin and NSAID use with risk of colorectal cancer according to genetic variants. JAMA 313, 1133-1142 (2015).
35. Bardou, M., Barkun, A. & Martel, M. Effect of statin therapy on colorectal cancer. Gut 59, 1572-1585 (2010).
36. Liu, Y. et al. Association between statin use and colorectal cancer risk: a meta-analysis of 42 studies. Cancer Causes Control 25, 237-249 (2014).
37. Limsui, D. et al. Postmenopausal hormone therapy and colorectal cancer risk by molecularly defined subtypes among older women. Gut 61, 1299-1305 (2012).
38. Ogino, S., Chan, A. T., Fuchs, C. S. & Giovannucci, E. Molecular pathological epidemiology of colorectal neoplasia: an emerging transdisciplinary and interdisciplinary field. Gut 60, 397-411 (2011).
39. Hanahan, D. & Weinberg, R. A. The hallmarks of cancer. Cell 100, 57-70 (2000).
40. Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646-674 (2011).
41. Colussi, D., Brandi, G., Bazzoli, F. & Ricciardiello, L. Molecular pathways involved in colorectal cancer: implications for disease behavior and prevention. Int. J. Mol. Sci. 14, 16365-16385 (2013).
42. Grady, W. M. & Carethers, J. M. Genomic and epigenetic instability in colorectal cancer pathogenesis. Gastroenterology 135, 1079-1099 (2008).
43. Fearon, E. R. & Vogelstein, B. A genetic model for colorectal tumorigenesis. Cell 61, 759-767 (1990).
44. Lengauer, C., Kinzler, K. W. & Vogelstein, B. Genetic instabilities in human cancers. Nature 396, 643-649 (1998).
45. Kinzler, K. W. & Vogelstein, B. Lessons from hereditary colorectal cancer. Cell 87, 159-170 (1996).
46. Zeki, S. S., Graham, T. A. & Wright, N. A. Stem cells and their implications for colorectal cancer. Nat. Rev. Gastroenterol. Hepatol. 8, 90-100 (2011).
47. Jones, S. et al. Comparative lesion sequencing provides insights into tumor evolution. Proc. Natl Acad. Sci. USA 105, 4283-4288 (2008).
48. Luo, Y. et al. Differences in DNA methylation signatures reveal multiple pathways of progression from adenoma to colorectal cancer. Gastroenterology 147, 418-429.e8 (2014).
49. Van Engeland, M., Derks, S., Smits, K. M., Meijer, G. A. & Herman, J. G. Colorectal cancer epigenetics: complex simplicity. J. Clin. Oncol. 29, 1382-1391 (2011).
50. Goldstein, N. S. Serrated pathway and APC (conventional)-type colorectal polyps: molecular-morphologic correlations, genetic pathways, and implications for classification. Am. J. Clin. Pathol. 125, 146-153 (2006).
51. Jass, J. R. Hyperplastic polyps and colorectal cancer: is there a link? Clin. Gastroenterol. Hepatol. 2, 1-8 (2004).
52. Bettington, M. et al. The serrated pathway to colorectal carcinoma: current concepts and challenges. Histopathology 62, 367-386 (2013).
53. Rex, D. K. et al. Serrated lesions of the colorectum: review and recommendations from an expert panel. Am. J. Gastroenterol. 107, 1315-1329 (2012).
54. Kambara, T. et al. BRAF mutation is associated with DNA methylation in serrated polyps and cancers of the colorectum. Gut 53, 1137-1144 (2004).
55. Noffsinger, A. E. Serrated polyps and colorectal cancer: new pathway to malignancy. Annu. Rev. Pathol. 4, 343-364 (2009).
56. Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature 487, 330-337 (2012).
57. Chittenden, T. W. et al. Functional classification analysis of somatically mutated genes in human breast and colorectal cancers. Genomics 91, 508-511 (2008).
58. Jubb, A. M., Bell, S. M. & Quirke, P. Methylation and colorectal cancer. J. Pathol. 195, 111-134 (2001).
59. Starr, T. K. et al. A transposon-based genetic screen in mice identifies genes altered in colorectal cancer. Science 323, 1747-1750 (2009).
60. Parsons, D. W. et al. Colorectal cancer: mutations in a signalling pathway. Nature 436, 792 (2005).
61. Brennan, C. W. et al. The somatic genomic landscape of glioblastoma. Cell 155, 462-477 (2013).
62. Grady, W. M. & Pritchard, C. C. Molecular alterations and biomarkers in colorectal cancer. Toxicol. Pathol. 42, 124-139 (2014).
63. Bardelli, A. et al. Mutational analysis of the tyrosine kinome in colorectal cancers. Science 300, 949 (2003).
64. Lao, V. V. & Grady, W. M. Epigenetics and colorectal cancer. Nat. Rev. Gastroenterol. Hepatol. 8, 686-700 (2011).
65. Kim, Y.-H. et al. CpG island methylation of genes accumulates during the adenoma progression step of the multistep pathogenesis of colorectal cancer. Genes Chromosomes Cancer 45, 781-789 (2006).
66. Bird, A. The essentials of DNA methylation. Cell 70, 5-8 (1992).
67. Worthley, D. L. et al. DNA methylation within the normal colorectal mucosa is associated with pathway-specific predisposition to cancer. Oncogene 29, 1653-1662 (2010).
68. Yamauchi, M. et al. Assessment of colorectal cancer molecular features along bowel subsites challenges the conception of distinct dichotomy of proximal versus distal colorectum. Gut 61, 847-854 (2012).
69. Rosty, C. et al. PIK3CA activating mutation in colorectal carcinoma: associations with molecular features and survival. PLoS ONE 8, e65479 (2013).
70. Galon, J. et al. Towards the introduction of the "Immunoscore" in the classification of malignant tumours. J. Pathol. 232, 199-209 (2014).
71. Kostic, A. D. et al. Genomic analysis identifies association of Fusobacterium with colorectal carcinoma. Genome Res. 22, 292-298 (2012).
72. Tahara, T. et al. Fusobacterium in colonic flora and molecular features of colorectal carcinoma. Cancer Res. 74, 1311-1318 (2014).
73. Mima, K. et al. Fusobacterium nucleatum and T cells in colorectal carcinoma. JAMA Oncol. 1, E1-E9 (2015).
74. Morris, E. J. A., Rutter, M. D., Finan, P. J., Thomas, J. D. & Valori, R. Post-colonoscopy colorectal cancer (PCCRC) rates vary considerably depending on the method used to calculate them: a retrospective observational population-based study of PCCRC in the English National Health Service. Gut 64, 1248-1256 (2014).
75. Kaminski, M. F. et al. Quality indicators for colonoscopy and the risk of interval cancer. N. Engl. J. Med. 362, 1795-1803 (2010).
76. Zauber, A. G. et al. Colonoscopic polypectomy and long-term prevention of colorectal-cancer deaths. N. Engl. J. Med. 366, 687-696 (2012).
77. Pox, C. P. et al. Efficacy of a nationwide screening colonoscopy program for colorectal cancer. Gastroenterology 142, 1460-1467.e2 (2012).
78. Winawer, S. J. et al. Prevention of colorectal cancer by colonoscopic polypectomy. The National Polyp Study Workgroup. N. Engl. J. Med. 329, 1977-1981 (1993).
79. Nishihara, R. et al. Long-term colorectal-cancer incidence and mortality after lower endoscopy. N. Engl. J. Med. 369, 1095-1105 (2013).
80. Corley, D. A. et al. Adenoma detection rate and risk of colorectal cancer and death. N. Engl. J. Med. 370, 1298-1306 (2014).
81. Sanduleanu, S. et al. Definition and taxonomy of interval colorectal cancers: a proposal for standardising nomenclature. Gut 64, 1257-1267 (2015).
82. Nagorni, A., Bjelakovic, G. & Petrovic, B. Narrow band imaging versus conventional white light colonoscopy for the detection of colorectal polyps. Cochrane Database Syst. Rev. 1, CD008361 (2012).
83. Pohl, J. et al. Pancolonic chromoendoscopy with indigo carmine versus standard colonoscopy for detection of neoplastic lesions: a randomised two-centre trial. Gut 60, 485-490 (2010).
84. Waye, J. D. et al. A retrograde-viewing device improves detection of adenomas in the colon: a prospective efficacy evaluation (with videos). Gastrointest. Endosc. 71, 551-556 (2010).
85. Leufkens, A. M. et al. Effect of a retrograde-viewing device on adenoma detection rate during colonoscopy: the TERRACE study. Gastrointest. Endosc. 73, 480-489 (2011).
86. DeMarco, D. C. et al. Impact of experience with a retrograde-viewing device on adenoma detection rates and withdrawal times during colonoscopy: the Third Eye Retroscope Study Group. Gastrointest. Endosc. 71, 542-550 (2010).
87. Van Gossum, A. et al. Capsule endoscopy versus colonoscopy for the detection of polyps and cancer. N. Engl. J. Med. 361, 264-270 (2009).
88. Spada, C. et al. Second-generation colon capsule endoscopy compared with colonoscopy. Gastrointest. Endosc. 74, 581-589.e1 (2011).
89. Spada, C. et al. Meta-analysis shows colon capsule endoscopy is effective in detecting colorectal polyps. Clin. Gastroenterol. Hepatol. 8, 516-522.e8 (2010).
90. Spada, C. et al. Colon capsule endoscopy: European Society of Gastrointestinal Endoscopy (ESGE) Guideline. Endoscopy 44, 527-536 (2012).
91. Rex, D. K. et al. Accuracy of capsule colonoscopy in detecting colorectal polyps in a screening population. Gastroenterology 148, 948-957.e2 (2015).
92. Sung, J. J. Y. et al. An updated Asia Pacific Consensus Recommendations on colorectal cancer screening. Gut 64, 121-132 (2014).
93. Kim, D. H. et al. CT colonography versus colonoscopy for the detection of advanced neoplasia. N. Engl. J. Med. 357, 1403-1412 (2007).
94. Pickhardt, P. J., Hassan, C., Halligan, S. & Marmo, R. Colorectal cancer: CT colonography and colonoscopy for detection - systematic review and meta-analysis. Radiology 259, 393-405 (2011).
95. Spada, C. et al. Colon capsule versus CT colonography in patients with incomplete colonoscopy: a prospective, comparative trial. Gut 64, 272-281 (2015).
96. Park, S. H. et al. CT colonography for detection and characterisation of synchronous proximal colonic lesions in patients with stenosing colorectal cancer. Gut 61, 1716-1722 (2012).
97. Plumb, A. A. et al. CT colonography in the English Bowel Cancer Screening Programme: national survey of current practice. Clin. Radiol. 68, 479-487 (2013).
98. De Wijkerslooth, T. R. et al. Burden of colonoscopy compared to non-cathartic CT-colonography in a colorectal cancer screening programme: randomised controlled trial. Gut 61, 1552-1559 (2012).
99. De Haan, M. C., van Gelder, R. E., Graser, A., Bipat, S. & Stoker, J. Diagnostic value of CT-colonography as compared to colonoscopy in an asymptomatic screening population: a meta-analysis. Eur. Radiol. 21, 1747-1763 (2011).
100. Pooler, B. D., Kim, D. H., Lam, V. P., Burnside, E. S. & Pickhardt, P. J. CT Colonography Reporting and Data System (C-RADS): benchmark values from a clinical screening program. Am. J. Roentgenol. 202, 1232-1237 (2014).
101. Stoop, E. M. et al. Participation and yield of colonoscopy versus non-cathartic CT colonography in population-based screening for colorectal cancer: a randomised controlled trial. Lancet Oncol. 13, 55-64 (2012).
102. Yee, J. et al. ACR Appropriateness Criteria colorectal cancer screening. J. Am. Coll. Radiol. 11, 543-551 (2014).
103. Spada, C. et al. Clinical indications for computed tomographic colonography: European Society of Gastrointestinal Endoscopy (ESGE) and European Society of Gastrointestinal and Abdominal Radiology (ESGAR) Guideline. Endoscopy 46, 897-915 (2014).
104. Grützmann, R. et al. Sensitive detection of colorectal cancer in peripheral blood by septin 9 DNA methylation assay. PLoS ONE 3, e3759 (2008).
105. Church, T. R. et al. Prospective evaluation of methylated SEPT9 in plasma for detection of asymptomatic colorectal cancer. Gut 63, 317-325 (2014).
106. Ahlquist, D. A. et al. Stool DNA and occult blood testing for screen detection of colorectal neoplasia. Ann. Intern. Med. 149, 441-450 (2008).
107. Imperiale, T. F. et al. Multitarget stool DNA testing for colorectal-cancer screening. N. Engl. J. Med. 370, 1287-1297 (2014).
108. Bosch, L. J. W. et al. Molecular tests for colorectal cancer screening. Clin. Colorectal Cancer 10, 8-23 (2011).
109. Kuipers, E. J. Colorectal cancer: screening - one small step for mankind, one giant leap for man. Nat. Rev. Clin. Oncol. 11, 5-6 (2014).
110. Brenner, H., Altenhofen, L., Stock, C. & Hoffmeister, M. Natural history of colorectal adenomas: birth cohort analysis among 3.6 million participants of screening colonoscopy. Cancer Epidemiol. Biomarkers Prev. 22, 1043-1051 (2013).
111. Schreuders, E. H. et al. Colorectal cancer screening: a global overview of existing programmes. Gut 64, 1637-1649 (2015).
112. Singh, H. et al. The reduction in colorectal cancer mortality after colonoscopy varies by site of the cancer. Gastroenterology 139, 1128-1137 (2010).
113. Brenner, H., Stock, C. & Hoffmeister, M. Effect of screening sigmoidoscopy and screening colonoscopy on colorectal cancer incidence and mortality: systematic review and meta-analysis of randomised controlled trials and observational studies. Br. Med. J. 2467, 1-12 (2014).
114. Le Clercq, C. M. C. et al. Metachronous colorectal cancers result from missed lesions and non-compliance with surveillance. Gastrointest. Endosc. 82, 325-333.e2 (2015).
115. Hoff, G., Grotmol, T., Skovlund, E. & Bretthauer, M. Risk of colorectal cancer seven years after flexible sigmoidoscopy screening: randomised controlled trial. BMJ 338, b1846 (2009).
116. Atkin, W. S. et al. Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial. Lancet 375, 1624-1633 (2010).
117. Segnan, N. et al. Once-only sigmoidoscopy in colorectal cancer screening: follow-up findings of the Italian Randomized Controlled Trial - SCORE. J. Natl Cancer Inst. 103, 1310-1322 (2011).
118. Van Putten, P. G. et al. Nurse endoscopists perform colonoscopies according to the international standard and with high patient satisfaction. Endoscopy 44, 1127-1132 (2012).
119. Stephens, M. et al. Non-physician endoscopists: a systematic review. World J. Gastroenterol. 21, 5056-5071 (2015).
120. Lansdorp-Vogelaar, I., van Ballegooijen, M., Zauber, A. G., Habbema, J. D. F. & Kuipers, E. J. Effect of rising chemotherapy costs on the cost savings of colorectal cancer screening. J. Natl Cancer Inst. 101, 1412-1422 (2009).
121. Inadomi, J. M. et al. Adherence to colorectal cancer screening: a randomized clinical trial of competing strategies. Arch. Intern. Med. 172, 575-582 (2012).
122. Van Dam, L., Kuipers, E. J., Steyerberg, E. W., van Leerdam, M. E. & de Beaufort, I. D. The price of autonomy: should we offer individuals a choice of colorectal cancer screening strategies? Lancet Oncol. 14, e38-e46 (2013).
123. Hol, L. et al. Screening for colorectal cancer: randomised trial comparing guaiac-based and immunochemical faecal occult blood testing and flexible sigmoidoscopy. Gut 59, 62-68 (2009).
124. Van Rossum, L. G. et al. Random comparison of guaiac and immunochemical fecal occult blood tests for colorectal cancer in a screening population. Gastroenterology 135, 82-90 (2008).
125. Wilschut, J. A. et al. Fecal occult blood testing when colonoscopy capacity is limited. J. Natl Cancer Inst. 103, 1741-1751 (2011).
126. Quintero, E. et al. Colonoscopy versus fecal immunochemical testing in colorectal-cancer screening. N. Engl. J. Med. 366, 697-706 (2012).
127. Kapidzic, A. et al. Attendance and yield over three rounds of population-based fecal immunochemical test screening. Am. J. Gastroenterol. 109, 1257-1264 (2014).
128. Van Roon, A. H. C. et al. Diagnostic yield improves with collection of 2 samples in fecal immunochemical test screening without affecting attendance. Clin. Gastroenterol. Hepatol. 9, 333-339 (2011).
129. Goede, S. L. et al. Cost-effectiveness of one versus two sample faecal immunochemical testing for colorectal cancer screening. Gut 62, 727-734 (2012).
130. Van Roon, A. H. C. et al. Random comparison of repeated faecal immunochemical testing at different intervals for population-based colorectal cancer screening. Gut 62, 409-415 (2012).
131. Hol, L. et al. Screening for colorectal cancer: random comparison of guaiac and immunochemical faecal occult blood testing at different cut-off levels. Br. J. Cancer 100, 1103-1110 (2009).
132. Van Heijningen, E. M. B. et al. Features of adenoma and colonoscopy associated with recurrent colorectal neoplasia based on a large community-based study. Gastroenterology 144, 1410-1418 (2013).
133. Lieberman, D. A. et al. Guidelines for colonoscopy surveillance after screening and polypectomy: a consensus update by the US Multi-Society Task Force on Colorectal Cancer. Gastroenterology 143, 844-857 (2012).
134. Martínez, M. E. et al. A pooled analysis of advanced colorectal neoplasia diagnoses after colonoscopic polypectomy. Gastroenterology 136, 832-841 (2009).
135. Løberg, M. et al. Long-term colorectal-cancer mortality after adenoma removal. N. Engl. J. Med. 371, 799-807 (2014).
136. Hassan, C. et al. Post-polypectomy colonoscopy surveillance: European Society of Gastrointestinal Endoscopy (ESGE) Guideline. Endoscopy 45, 842-851 (2013).
137. Cairns, S. R. et al. Guidelines for colorectal cancer screening and surveillance in moderate and high risk groups. Gut 59, 666-689 (2010).
138. Lieberman, D. A. et al. Low rate of large polyps (>9 mm) within 10 years after an adequate baseline colonoscopy with no polyps. Gastroenterology 147, 343-350 (2014).
139. Lansdorp-Vogelaar, I. et al. Personalizing age of cancer screening cessation based on comorbid conditions: Model estimates of harms and benefits. Ann. Intern. Med. 161, 104-112 (2014).
140. van Hees, F. et al. Should colorectal cancer screening be considered in elderly persons without previous screening? Ann. Intern. Med. 160, 750-759 (2014).
141. Hazewinkel, Y. et al. Prevalence of serrated polyps and association with synchronous advanced neoplasia in screening colonoscopy. Endoscopy 46, 219-224 (2014).
142. Ijspeert, J. E. G. et al. Development and validation of the WASP classification system for optical diagnosis of adenomas, hyperplastic polyps and sessile serrated adenomas/polyps. Gut http://dx.doi.org/10.1136/ gutjnl-2014-308411 (2015).
143. Jeffery, G. M., Hickey, B. E. & Hider, P. Follow-up strategies for patients treated for non-metastatic colorectal cancer. Cochrane Database Syst. Rev. 1, CD002200 (2002).
144. Primrose, J. N. et al. Effect of 3 to 5 years of scheduled CEA and CT follow-up to detect recurrence of colorectal cancer: the FACS randomized clinical trial. JAMA 311, 263-270 (2014).
145. Brenner, H. et al. Progress in colorectal cancer survival in Europe from the late 1980s to the early 21st century: the EUROCARE study. Int. J. Cancer 131, 1649-1658 (2012).
146. Breugom, A. J. et al. Quality assurance in the treatment of colorectal cancer: the EURECCA initiative. Ann. Oncol. 25, 1485-1492 (2014).
147. Van de Velde, C. J. H. et al. EURECCA colorectal: multidisciplinary management: European consensus conference colon & rectum. Eur. J. Cancer 50, 1.e1-1.e34 (2014).
148. Van de Velde, C. J. H. et al. Experts reviews of the multidisciplinary consensus conference colon and rectal cancer 2012: science, opinions and experiences from the experts of surgery. Eur. J. Surg. Oncol. 40, 454-468 (2014).
149. Quirke, P., West, N. P. & Nagtegaal, I. D. EURECCA consensus conference highlights about colorectal cancer clinical management: the pathologists expert review. Virchows Arch. 464, 129-134 (2014).
150. Valentini, V. et al. EURECCA consensus conference highlights about rectal cancer clinical management: the radiation oncologist's expert review. Radiother. Oncol. 110, 195-198 (2014).
151. Tudyka, V. et al. EURECCA consensus conference highlights about colon and rectal cancer multidisciplinary management: the radiology experts review. Eur. J. Surg. Oncol. 40, 469-475 (2014).
152. Van de Velde, C. J. H. et al. EURECCA colorectal: multidisciplinary mission statement on better care for patients with colon and rectal cancer in Europe. Eur. J. Cancer 49, 2784-2790 (2013).
153. Rutten, H. J. T., den Dulk, M., Lemmens, V. E., van de Velde, C. J. H. & Marijnen, C. A. M. Controversies of total mesorectal excision for rectal cancer in elderly patients. Lancet Oncol. 9, 494-501 (2008).
154. Gooiker, G. A. et al. Risk factors for excess mortality in the first year after curative surgery for colorectal cancer. Ann. Surg. Oncol. 19, 2428-2434 (2012).
155. Van den Broek, C. B. M. et al. The survival gap between middle-aged and elderly colon cancer patients. Time trends in treatment and survival. Eur. J. Surg. Oncol. 37, 904-912 (2011).
156. Dekker, J. W. T. et al. Cause of death the first year after curative colorectal cancer surgery; a prolonged impact of the surgery in elderly colorectal cancer patients. Eur. J. Surg. Oncol. 40, 1481-1487 (2014).
157. Mulder, S. A. et al. Prevalence and prognosis of synchronous colorectal cancer: a Dutch population-based study. Cancer Epidemiol. 35, 442-447 (2011).
158. Taylor, F. G. M. et al. Preoperative magnetic resonance imaging assessment of circumferential resection margin predicts disease-free survival and local recurrence: 5-year follow-up results of the MERCURY study. J. Clin. Oncol. 32, 34-43 (2014).
159. Veldkamp, R. et al. Laparoscopic surgery versus open surgery for colon cancer: short-term outcomes of a randomised trial. Lancet Oncol. 6, 477-484 (2005).
160. Bonjer, H. J. et al. A randomized trial of laparoscopic versus open surgery for rectal cancer. N. Engl. J. Med. 372, 1324-1332 (2015).
161. Colon Cancer Laparoscopic or Open Resection Study Group et al. Survival after laparoscopic surgery versus open surgery for colon cancer: long-term outcome of a randomised clinical trial. Lancet Oncol. 10, 44-52 (2009).
162. Chen, J. et al. Meta-analysis of temporary ileostomy versus colostomy for colorectal anastomoses. Acta Chir. Belg. 113, 330-339 (2013).
163. Van Hooft, J. E. et al. Self-expandable metal stents for obstructing colonic and extracolonic cancer: European Society of Gastrointestinal Endoscopy (ESGE) Clinical Guideline. Endoscopy 46, 990-1053 (2014).
164. Fiori, E. et al. Palliative management for patients with subacute obstruction and stage IV unresectable rectosigmoid cancer: colostomy versus endoscopic stenting: final results of a prospective randomized trial. Am. J. Surg. 204, 321-326 (2012).
165. De Graaf, E. J. R. et al. Transanal endoscopic microsurgery versus total mesorectal excision of T1 rectal adenocarcinomas with curative intention. Eur. J. Surg. Oncol. 35, 1280-1285 (2009).
166. Doornebosch, P. G. et al. Transanal endoscopic microsurgery for T1 rectal cancer: size matters! Surg. Endosc. 26, 551-557 (2011).
167. Lezoche, E. et al. Randomized clinical trial of endoluminal locoregional resection versus laparoscopic total mesorectal excision for T2 rectal cancer after neoadjuvant therapy. Br. J. Surg. 99, 1211-1218 (2012).
168. Martin-Perez, B., Andrade-Ribeiro, G. D., Hunter, L. & Atallah, S. A systematic review of transanal minimally invasive surgery (TAMIS) from 2010 to 2013. Tech. Coloproctol. 18, 775-788 (2014).
169. Nagtegaal, I. D., Marijnen, C. A. M., Kranenbarg, E. K., van de Velde, C. J. H. & van Krieken, J. H. Circumferential margin involvement is still an important predictor of local recurrence in rectal carcinoma: not one millimeter but two millimeters is the limit. Am. J. Surg. Pathol. 26, 350-357 (2002).
170. Quirke, P. et al. Effect of the plane of surgery achieved on local recurrence in patients with operable rectal cancer: a prospective study using data from the MRC CR07 and NCIC-CTG CO16 randomised clinical trial. Lancet 373, 821-828 (2009).
171. Heald, R. J., Husband, E. M. & Ryall, R. D. The mesorectum in rectal cancer surgery - the clue to pelvic recurrence? Br. J. Surg. 69, 613-616 (1982).
172. Ramji, K. M. et al. Comparison of clinical and economic outcomes between robotic, laparoscopic, and open rectal cancer surgery: early experience at a tertiary care center. Surg. Endosc. http://dx.doi.org/ 10.1007/s00464-015-4390-8 (2015).
173. Kapiteijn, E. et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N. Engl. J. Med. 345, 638-646 (2001).
174. Folkesson, J. et al. Swedish rectal cancer trial: long lasting benefits from radiotherapy on survival and local recurrence rate. J. Clin. Oncol. 23, 5644-5650 (2005).
175. Sebag-Montefiore, D. et al. Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial. Lancet 373, 811-820 (2009).
176. Van Gijn, W. et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial. Lancet Oncol. 12, 575-582 (2011).
177. Pettersson, D. et al. Interim analysis of the Stockholm III trial of preoperative radiotherapy regimens for rectal cancer. Br. J. Surg. 97, 580-587 (2010).
178. Juul, T. et al. Low anterior resection syndrome and quality of life. Dis. Colon Rectum 57, 585-591 (2014).
179. García, M. et al. Phase II study of preoperative bevacizumab, capecitabine and radiotherapy for resectable locally-advanced rectal cancer. BMC Cancer 15, 59 (2015).
180. Beyond TME Collaborative. Consensus statement on the multidisciplinary management of patients with recurrent and primary rectal cancer beyond total mesorectal excision planes. Br. J. Surg. 100, E1-E33 (2013).
181. Habr-Gama, A., Perez, R. O., São Julião, G. P., Proscurshim, I. & Gama-Rodrigues, J. Nonoperative approaches to rectal cancer: a critical evaluation. Semin. Radiat. Oncol. 21, 234-239 (2011).
182. Maas, M. et al. Wait-and-see policy for clinical complete responders after chemoradiation for rectal cancer. J. Clin. Oncol. 29, 4633-4640 (2011).
183. Dalton, R. S. J. et al. A single-centre experience of chemoradiotherapy for rectal cancer: is there potential for nonoperative management? Colorectal Dis. 14, 567-571 (2012).
184. Fujita, S. et al. Postoperative morbidity and mortality after mesorectal excision with and without lateral lymph node dissection for clinical stage II or stage III lower rectal cancer (JCOG0212): results from a multicentre, randomised controlled, non-inferiority trial. Lancet Oncol. 13, 616-621 (2012).
185. Pahlman, L. et al. The Swedish rectal cancer registry. Br. J. Surg. 94, 1285-1292 (2007).
186. Wibe, A. et al. Effect of hospital caseload on long-term outcome after standardization of rectal cancer surgery at a national level. Br. J. Surg. 92, 217-224 (2005).
187. Birkmeyer, J. D. et al. Hospital volume and surgical mortality in the United States. N. Engl. J. Med. 346, 1128-1137 (2002).
188. Kehlet, H. Multimodal approach to control postoperative pathophysiology and rehabilitation. Br. J. Anaesth. 78, 606-617 (1997).
189. Kehlet, H. & Mogensen, T. Hospital stay of 2 days after open sigmoidectomy with a multimodal rehabilitation programme. Br. J. Surg. 86, 227-230 (1999).
190. Lassen, K. et al. Consensus review of optimal perioperative care in colorectal surgery: Enhanced Recovery After Surgery (ERAS) Group recommendations. Arch. Surg. 144, 961-969 (2009).
191. Boelens, P. G. et al. Reduction of postoperative ileus by early enteral nutrition in patients undergoing major rectal surgery. Ann. Surg. 259, 649-655 (2014).
192. Sauer, R. et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N. Engl. J. Med. 351, 1731-1740 (2004).
193. Glimelius, B., Tiret, E., Cervantes, A. & Arnold, D. Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 24, vi81-vi88 (2013).
194. Labianca, R. et al. Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 24, vi64-vi72 (2013).
195. McCleary, N. J. et al. Impact of age on the efficacy of newer adjuvant therapies in patients with stage II/III colon cancer: findings from the ACCENT database. J. Clin. Oncol. 31, 2600-2606 (2013).
196. Van Cutsem, E., Cervantes, A., Nordlinger, B. & Arnold, D. Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 25, iii1-iii9 (2014).
197. Amado, R. G. et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J. Clin. Oncol. 26, 1626-1634 (2008).
198. Douillard, J.-Y. et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N. Engl. J. Med. 369, 1023-1034 (2013).
199. Ferrara, N., Hillan, K. J., Gerber, H.-P. & Novotny, W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat. Rev. Drug Discov. 3, 391-400 (2004).
200. Willett, C. G. et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat. Med. 10, 145-147 (2004).
201. Giantonio, B. J. et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J. Clin. Oncol. 25, 1539-1544 (2007).
202. Kubicka, S. et al. Bevacizumab plus chemotherapy continued beyond first progression in patients with metastatic colorectal cancer previously treated with bevacizumab plus chemotherapy: ML18147 study KRAS subgroup findings. Ann. Oncol. 24, 2342-2349 (2013).
203. Van Cutsem, E. et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a Phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J. Clin. Oncol. 30, 3499-3506 (2012).
204. Tomlinson, J. S. et al. Actual 10-year survival after resection of colorectal liver metastases defines cure. J. Clin. Oncol. 25, 4575-4580 (2007).
205. Evrard, S. et al. Combined ablation and resection (CARe) as an effective parenchymal sparing treatment for extensive colorectal liver metastases. PLoS ONE 9, e114404 (2014).
206. Ayez, N. et al. Outcome of microscopic incomplete resection (R1) of colorectal liver metastases in the era of neoadjuvant chemotherapy. Ann. Surg. Oncol. 19, 1618-1627 (2012).
207. Falcone, A. et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J. Clin. Oncol. 25, 1670-1676 (2007).
208. Heinemann, V. et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol. 15, 1065-1075 (2014).
209. Benoist, S. et al. Complete response of colorectal liver metastases after chemotherapy: does it mean cure? J. Clin. Oncol. 24, 3939-3945 (2006).
210. Simkens, L. H. J., Koopman, M. & Punt, C. J. A. Optimal duration of systemic treatment in metastatic colorectal cancer. Curr. Opin. Oncol. 26, 448-453 (2014).
211. Grothey, A. et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 381, 303-312 (2013).
212. Smith, J. J. & Weiser, M. R. Outcomes in non-metastatic colorectal cancer. J. Surg. Oncol. 110, 518-526 (2014).
213. Juul, T. et al. International validation of the low anterior resection syndrome score. Ann. Surg. 259, 728-734 (2014).
214. Feddern, M.-L., Jensen, T. S. & Laurberg, S. Chronic pain in the pelvic area or lower extremities after rectal cancer treatment and its impact on quality of life: a population-based cross-sectional study. Pain 156, 1765-1771 (2015).
215. De Caluwé, L., Van Nieuwenhove, Y. & Ceelen, W. P. Preoperative chemoradiation versus radiation alone for stage II and III resectable rectal cancer. Cochrane Database Syst. Rev. 2, CD006041 (2013).
216. Bregendahl, S., Emmertsen, K. J., Lindegaard, J. C. & Laurberg, S. Urinary and sexual dysfunction in women after resection with and without preoperative radiotherapy for rectal cancer: a population-based cross-sectional study. Colorectal Dis. 17, 26-37 (2015).
217. Gilbert, A. et al. Systematic review of radiation therapy toxicity reporting in randomized controlled trials of rectal cancer: a comparison of patient-reported outcomes and clinician toxicity reporting. Int. J. Radiat. Oncol. Biol. Phys. 92, 555-567 (2015).
218. Diouf, M. et al. Could baseline health-related quality of life (QoL) predict overall survival in metastatic colorectal cancer? The results of the GERCOR OPTIMOX 1 study. Health Qual. Life Outcomes 12, 69 (2014).
219. Otto, S. J. et al. Association of change in physical activity and body weight with quality of life and mortality in colorectal cancer: a systematic review and meta-analysis. Support. Care Cancer 23, 1237-1250 (2015).
220. Averyt, J. C. & Nishimoto, P. W. Psychosocial issues in colorectal cancer survivorship: the top ten questions patients may not be asking. J. Gastrointest. Oncol. 5, 395-400 (2014).
221. Martínez, M. E. et al. One-year risk for advanced colorectal neoplasia: U. S. versus U. K. risk-stratification guidelines. Ann. Intern. Med. 157, 856-864 (2012).
222. Gao, W., Gulliford, M., Bennett, M. I., Murtagh, F. E. M. & Higginson, I. J. Managing cancer pain at the end of life with multiple strong opioids: a population-based retrospective cohort study in primary care. PLoS ONE 9, e79266 (2014).
223. Zhong, S. et al. Association between physical activity and mortality in breast cancer: a meta-analysis of cohort studies. Eur. J. Epidemiol. 29, 391-404 (2014).
224. Davies, R. J., Miller, R. & Coleman, N. Colorectal cancer screening: prospects for molecular stool analysis. Nat. Rev. Cancer 5, 199-209 (2005).
225. Towler, B. P., Irwig, L., Glasziou, P., Weller, D. & Kewenter, J. Screening for colorectal cancer using the faecal occult blood test, hemoccult. Cochrane Database Syst. Rev. 2, CD001216 (2000).
226. Brenner, H. & Tao, S. Superior diagnostic performance of faecal immunochemical tests for haemoglobin in a head-to-head comparison with guaiac based faecal occult blood test among 2235 participants of screening colonoscopy. Eur. J. Cancer 49, 3049-3054 (2013).
227. Schoen, R. E. et al. Colorectal-cancer incidence and mortality with screening flexible sigmoidoscopy. N. Engl. J. Med. 366, 2345-2357 (2012).
228. Brenner, H., Chang-Claude, J., Seiler, C. M., Rickert, A. & Hoffmeister, M. Protection from colorectal cancer after colonoscopy: a population-based, case-control study. Ann. Intern. Med. 154, 22-30 (2011).
229. Cash, B. D. et al. CT colonography of a medicare-aged population: outcomes observed in an analysis of more than 1400 patients. Am. J. Roentgenol. 199, 27-34 (2012).